Differences between revisions 6 and 7
Revision 6 as of 2006-10-12 17:56:10
Size: 2110
Editor: GaryBader
Comment:
Revision 7 as of 2006-10-12 18:23:08
Size: 2217
Editor: GaryBader
Comment:
Deletions are marked like this. Additions are marked like this.
Line 26: Line 26:
 * Next step: Allan, Mirit, David, Gary, Aditya, Scooter, Alex; also general interest from Nathan, Kristina (GenMAPP editing), Ethan, Ben (BioPAX editing)  * Next step: a special interest group should get together to hash the above out further. Current interested people are: Allan, Mirit, David, Gary, Aditya, Scooter, Alex; also general interest from Nathan, Kristina (GenMAPP editing), Ethan, Ben (BioPAX editing)

Day 1

MIM discussion

  • Allan began by presenting his mapping from MIM shapes to Cytoscape graphical elements, presented on ["Molecular Interaction Maps"].
  • Need to map MIM to both model and view
    • How to represent 'non covalent binding'?
      • Model: Best mapped to a group. A and B are connected and are part of the group.
      • View: this is a use case for the group view
    • Asymmetric binding
      • Model: Regular edge between A and B, just needs a specific edge type
      • View: New type of custom edge graphic (will take some care with Nerius' edge drawing code)
    • Representation of multimolecular complexes
      • Model: A group of groups
      • View: part of the use case for group view
    • Covalent modification of protein A (post-translational modification = PTM)
      • Model: A is a node (representing unmodified protein); central node is a node (represented modified A) - every state is represented as a node. The PTM e.g. P is not a node, it is an annotation on the 'central' state node. The edge between A and its state is of type 'state of'. The set of all states is grouped to represent the set of all states of A.
      • View: Constraint: the states always move together (would be like a template)
    • Cleavage of of a covalent modification of protein A
      • Model: Hyperedge containing node1: Phtase (hyperedge attribute: enzyme), node2: phosphorylated A, node3: unphosphorylated A
      • View: Use case for hyperedge view
  • General constraints for automatic layout and the editor
    • Snap to grid
    • All lines need to be routed with only right or acute angles
    • Central node is only there if it is used (connected to something else in the diagram)
  • Next step: a special interest group should get together to hash the above out further. Current interested people are: Allan, Mirit, David, Gary, Aditya, Scooter, Alex; also general interest from Nathan, Kristina (GenMAPP editing), Ethan, Ben (BioPAX editing)
  • Implementation: Cytoscape core would ensure that the model and view requirements are met. Users: like GenMAPP, MIM, BioPAX editing would use the core functionality to create their own plugins that implemented their own pathway editing features.

CytoscapeRetreat2006/UserMeetingNotes (last edited 2009-02-12 01:03:40 by localhost)

Funding for Cytoscape is provided by a federal grant from the U.S. National Institute of General Medical Sciences (NIGMS) of the Na tional Institutes of Health (NIH) under award number GM070743-01. Corporate funding is provided through a contract from Unilever PLC.

MoinMoin Appliance - Powered by TurnKey Linux